BRIEF

on AMOEBA (EPA:ALMIB)

Amoéba and Koppert are testing AXPERA technology in Brazil

Stock price chart of AMOEBA (EPA:ALMIB) showing fluctuations.

Amoéba, a company specializing in microbiological solutions, in partnership with Koppert, conducted a testing program on soybean and orange crops in Brazil. These trials aimed to evaluate the AXPERA biofungicide technology in the leading producer of these crops. The Brazilian market, with an estimated potential of €1 billion by 2025, presents a favorable environment for the development of bio-inputs.

Initial results on soybeans show effectiveness against Asian rust, and on orange trees, a potential reduction in copper use against bacterial canker. Brazil could be an expansion platform for Amoéba, with commercialization planned for 2028, subject to obtaining the necessary approvals.

R. E.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all AMOEBA news